(Q40488158)

21 September 2017

1 reference

title

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia (English)

1 reference

21 September 2017

1 reference

1 reference

M I Wilde

1

1 reference

21 September 2017

A Fitton

series ordinal

2

1 reference

21 September 2017

E M Sorkin

series ordinal

3

1 reference

21 September 2017

publication date

1 May 1993

1 reference

21 September 2017

1 reference

21 September 2017

volume

3

1 reference

21 September 2017

issue

3

1 reference

21 September 2017

page(s)

258-277

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199303030-00007

21 September 2017

exact match

0 references

cites work

Prostatism. I. The correlation between symptoms, cystometric and urodynamic findings

1 reference

12 December 2020

Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy

1 reference

12 December 2020

Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin

1 reference

12 December 2020

Pharmacology of terazosin.

1 reference

12 December 2020

Future directions in the management of benign prostatic hyperplasia

1 reference

12 December 2020

In vitro characterization of the alpha-adrenoceptors in human prostate

1 reference

12 December 2020

Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia

1 reference

12 December 2020

Human benign prostatic hyperplasia: A stromal disease? New perspectives by quantitative morphology

1 reference

12 December 2020

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Comparative trials of terazosin with other antihypertensive agents

1 reference

12 December 2020

α1- and α2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethra

1 reference

12 December 2020

Nonoperative management of benign prostatic hyperplasia

1 reference

12 December 2020

Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin

1 reference

12 December 2020

Terazosin: a new alpha adrenoceptor blocking drug

1 reference

12 December 2020

Comparison of the alpha-adrenoceptor characteristics in human and canine prostate

1 reference

12 December 2020

Terazosin: Pharmacokinetics and the effect of age and dose on the incidence of adverse events

1 reference

12 December 2020

Comparison of testosterone, 5alpha-dihydrotestosterone and 5alpha-adrostane-3beta, 17beta-diol metabolisms in human normal and hyperplastic prostates

1 reference

12 December 2020

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy.

1 reference

12 December 2020

Alpha 1 adrenergic receptors in canine lower genitourinary tissues: insight into development and function.

1 reference

12 December 2020

Epidemiology of benign prostatic hyperplasia: present knowledge and studies needed.

1 reference

12 December 2020

The pathogenesis of benign prostatic hyperplasia

1 reference

12 December 2020

Efficacy of terazosin in patients with benign prostatic hyperplasia

1 reference

12 December 2020

Terazosin: an effective once-daily monotherapy for the treatment of hypertension

1 reference

12 December 2020

The influence of food on the oral bioavailability of terazosin.

1 reference

12 December 2020

A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra

1 reference

12 December 2020

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia.

1 reference

12 December 2020

The use of alpha-adrenergic blockers in benign prostatic obstruction

1 reference

12 December 2020

Effect of age on the pharmacokinetics of orally and intravenously administered terazosin

1 reference

12 December 2020

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

12 December 2020

The flow rate nomogram: II. Clinical correlation.

1 reference

12 December 2020

The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain

1 reference

12 December 2020

Urodynamics in benign prostatic hyperplasia: a survey.

1 reference

12 December 2020

The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia

1 reference

12 December 2020

Changes in the Metabolism of Dihydrotestosterone in the Hyperplastic Human Prostate*

1 reference

12 December 2020

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension

1 reference

12 December 2020

Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate.

1 reference

12 December 2020

Origin and evolution of benign prostatic enlargement

1 reference

12 December 2020

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial

1 reference

12 December 2020

Efficacy of terazosin as an antihypertensive agent.

1 reference

12 December 2020

Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding

1 reference

12 December 2020

Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia

1 reference

12 December 2020

Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial

1 reference

12 December 2020

Etiology and disease process of benign prostatic hyperplasia

1 reference

12 December 2020

Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans

1 reference

12 December 2020

Analysis of presenting symptoms in prostatism

1 reference

12 December 2020

Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study

1 reference

12 December 2020

The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH

1 reference

12 December 2020

The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin

1 reference

12 December 2020

Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy

1 reference

12 December 2020

Pharmacokinetics of terazosin

1 reference

12 December 2020

Clinical experience with alpha-adrenoceptor antagonists in benign prostatic hypertrophy

1 reference

12 December 2020

10.2165/00002512-199303030-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

1051828140

0 references

1 reference